{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:25:10Z","timestamp":1791923110214,"version":"4.3.4"},"reference-count":266,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander Foundation","doi-asserted-by":"publisher","award":["2023.004.1"],"award-info":[{"award-number":["2023.004.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["PH 412\/1-1"],"award-info":[{"award-number":["PH 412\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"German Jos\u00e9 Carreras Foundation for Leucemia","doi-asserted-by":"publisher","award":["10\/R2023"],"award-info":[{"award-number":["10\/R2023"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.medj.2026.101031","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:02:54Z","timestamp":1772208174000},"page":"101031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: Mechanisms and implications"],"prefix":"10.1016","volume":"7","author":[{"given":"Amelie","family":"Muth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Holzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit L.","family":"Buecklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3918-7795","authenticated-orcid":false,"given":"Nora","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101031_bib1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101031_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101031_bib3","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.medj.2026.101031_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib6","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101031_bib7","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.medj.2026.101031_bib10","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101031_bib11","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101031_bib12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib14","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101031_bib15","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.medj.2026.101031_bib16","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101031_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell Dysfunction in Cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101031_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jim.2017.03.009","article-title":"Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns","volume":"453","author":"Bengsch","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.medj.2026.101031_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41587-019-0206-z","article-title":"Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion","volume":"37","author":"Satpathy","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.medj.2026.101031_bib23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory CD8+ T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib26","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory","volume":"37","author":"Doering","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf. Open Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41590-019-0403-4","article-title":"Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection","volume":"20","author":"Yao","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib34","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101031_bib35","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1128\/JVI.00889-12","article-title":"Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection","volume":"86","author":"Angelosanto","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.medj.2026.101031_bib36","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41590-022-01337-5","article-title":"Divergent clonal differentiation trajectories of T cell exhaustion","volume":"23","author":"Daniel","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8(+) T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib40","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib43","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101031_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib45","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib46","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41590-020-0760-z","article-title":"Early precursor T cells establish and propagate T cell exhaustion in chronic infection","volume":"21","author":"Utzschneider","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41590-021-00868-7","article-title":"BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells","volume":"22","author":"Yao","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib49","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ni.2158","article-title":"The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets","volume":"12","author":"Yang","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib50","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41590-022-01338-4","article-title":"Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics","volume":"23","author":"Giles","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41586-022-05105-1","article-title":"MYB orchestrates T cell exhaustion and response to checkpoint inhibition","volume":"609","author":"Tsui","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"CD4(+) T Cell Help Is Required for the Formation of a Cytolytic CD8(+) T Cell Subset that Protects against Chronic Infection and Cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1(+) Stem-like CD8(+) T Cells during Chronic Infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib54","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41590-021-00965-7","article-title":"BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection","volume":"22","author":"Chen","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib55","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220679","article-title":"Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection","volume":"220","author":"Kasmani","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2026.101031_bib56","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib57","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","article-title":"Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction","volume":"567","author":"Liu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib58","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.immuni.2017.11.021","article-title":"Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection","volume":"47","author":"Man","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2009.06.019","article-title":"A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection","volume":"31","author":"Shin","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2026.101031_bib61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005177","article-title":"CD39 Expression Identifies Terminally Exhausted CD8+ T Cells","volume":"11","author":"Gupta","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.medj.2026.101031_bib63","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib64","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1172\/JCI26856","article-title":"Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection","volume":"116","author":"Brooks","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101031_bib65","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.2606","article-title":"T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion","volume":"14","author":"Utzschneider","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib66","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib67","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41590-021-00979-1","article-title":"Epigenetic scars of CD8(+) T cell exhaustion persist after cure of chronic infection in humans","volume":"22","author":"Yates","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib68","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41590-021-00975-5","article-title":"Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation","volume":"22","author":"Abdel-Hakeem","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib69","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib70","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.immuni.2016.10.028","article-title":"Dynamic Changes in Chromatin Accessibility Occur in CD8(+) T Cells Responding to Viral Infection","volume":"45","author":"Scott-Browne","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189162","article-title":"T cell exhaustion in human cancers","volume":"1879","author":"Kang","year":"2024","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib72","article-title":"Epigenetic regulation of CD8(+) T cell exhaustion: recent advances and update","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib73","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","article-title":"T cell dysfunction and therapeutic intervention in cancer","volume":"25","author":"Zebley","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib74","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/mt.2014.91","article-title":"Epigenetic manipulation restores functions of defective CD8+ T cells from chronic viral infection","volume":"22","author":"Zhang","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.medj.2026.101031_bib75","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib77","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.immuni.2023.11.005","article-title":"Stat5 opposes the transcription factor Tox and rewires exhausted CD8(+) T cells toward durable effector-like states during chronic antigen exposure","volume":"56","author":"Beltra","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib78","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41590-024-01961-3","article-title":"Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control","volume":"25","author":"Weiss","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","article-title":"Beyond Bruton\u2019s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody\u2013drug conjugates, CAR T-cells, and novel agents","volume":"16","author":"Jain","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117753","article-title":"Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy","volume":"181","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.medj.2026.101031_bib81","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101031_bib82","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.1700559","article-title":"The Loss of TET2 Promotes CD8(+) T Cell Memory Differentiation","volume":"200","author":"Carty","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib84","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41467-017-02187-8","article-title":"Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity","volume":"8","author":"He","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101031_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/science.adj3020","article-title":"Nutrient-driven histone code determines exhausted CD8(+) T cell fates","volume":"387","author":"Ma","year":"2025","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib86","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib87","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101031_bib88","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of T-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.medj.2026.101031_bib89","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8+ T cell metabolism in infection and cancer","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib90","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41590-023-01733-5","article-title":"Metabolic waypoints during T cell differentiation","volume":"25","author":"Wilfahrt","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib91","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/imm.13575","article-title":"Metabolic plasticity and regulation of T cell exhaustion","volume":"167","author":"Li","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.medj.2026.101031_bib92","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","article-title":"Metabolic Instruction of Immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101031_bib93","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.medj.2026.101031_bib94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41590-018-0045-y","article-title":"Metabolic exhaustion in infection, cancer and autoimmunity","volume":"19","author":"McKinney","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib95","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.celrep.2016.06.078","article-title":"Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host","volume":"16","author":"Schurich","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2026.101031_bib96","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib97","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101031_bib98","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.4049\/jimmunol.1502464","article-title":"Suppression of Glut1 and Glucose Metabolism by Decreased Akt\/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia","volume":"197","author":"Siska","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib99","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101031_bib100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib101","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib102","doi-asserted-by":"crossref","first-page":"14336","DOI":"10.1073\/pnas.1221740110","article-title":"CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability","volume":"110","author":"van der Windt","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101031_bib103","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib104","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib105","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood-2024-211459","article-title":"Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R\/R LBCL","volume":"144","author":"Magno","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib106","doi-asserted-by":"crossref","first-page":"PO-003","DOI":"10.1158\/2643-3249.LYMPHOMA24-PO-003","article-title":"Abstract PO-003: Peripheral blood and tumor tissue biomarkers associated with epcoritamab response in patients with relapsed or refractory diffuse large B-cell lymphoma: Data from the dose-expansion cohort of the phase 1\/2 EPCORE NHL-1 trial (NCT03625037)","volume":"5","author":"Wielgos-Bonvallet","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.medj.2026.101031_bib107","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2023-190201","article-title":"Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts","volume":"142","author":"Chong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib108","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2019-123933","article-title":"Pharmacodynamic Effects and Immune Correlates of Response to the CD20\/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"134","author":"Hernandez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib109","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2023-188970","article-title":"Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response","volume":"142","author":"Corrado","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib110","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.medj.2026.101031_bib111","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib112","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2026.101031_bib113","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-Cell Characteristics Impact Response and Resistance to T-Cell\u2013Redirecting Bispecific Antibodies in Multiple Myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101031_bib114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2026.101031_bib117","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib118","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41375-024-02387-4","article-title":"Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse","volume":"38","author":"Kazerani","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2026.101031_bib119","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib120","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/0008-5472.CAN-03-3066","article-title":"Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance","volume":"64","author":"Zippelius","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2026.101031_bib121","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.coi.2010.02.005","article-title":"Features of responding T cells in cancer and chronic infection","volume":"22","author":"Kim","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib122","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib123","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood-2021-144843","article-title":"A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network","volume":"138","author":"Van Der Sluis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib125","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2023-179776","article-title":"Molecular Mechanisms Underlying Response and Resistance to Glofitamab","volume":"142","author":"Nassiri","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib126","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bjh.19104","article-title":"Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study","volume":"203","author":"Ocadlikova","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.medj.2026.101031_bib127","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2023-181418","article-title":"Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib128","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.medj.2026.101031_bib129","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood-2023-173550","article-title":"Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1\/2 MajesTEC-1 Study of Patients with Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib130","first-page":"3078","article-title":"Clonal CD8+ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma","volume":"109","author":"Krzysiek","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.medj.2026.101031_bib131","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101031_bib132","article-title":"Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas","volume":"2024","author":"Falchi","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.medj.2026.101031_bib133","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101031_bib134","doi-asserted-by":"crossref","first-page":"962552","DOI":"10.3389\/fimmu.2022.962552","article-title":"Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib135","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Foa","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101031_bib136","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.medj.2026.101031_bib137","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib138","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1096\/fj.13-236992","article-title":"BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein","volume":"28","author":"Buffa","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.medj.2026.101031_bib139","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2026.101031_bib140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-019-0151-z","article-title":"Development of molecular and pharmacological switches for chimeric antigen receptor T cells","volume":"8","author":"Wu","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib141","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2021011822","article-title":"Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab","volume":"138","author":"Puzzolo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib142","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1182\/blood-2023-179286","article-title":"Accomplices in Cure: Blinatumomab+ Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion","volume":"142","author":"Philipp","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib143","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145459","article-title":"BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia","volume":"131","author":"Kong","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101031_bib144","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41419-022-05123-x","article-title":"BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.medj.2026.101031_bib145","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101031_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2026.101031_bib147","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101031_bib148","article-title":"Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy","author":"Hou","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.medj.2026.101031_bib149","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T Cell Exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib150","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease","volume":"44","author":"Attanasio","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib151","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2026.101031_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107827","article-title":"The PD-1 Pathway Regulates Development and Function of Memory CD8(+) T Cells following Respiratory Viral Infection","volume":"31","author":"Pauken","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2026.101031_bib153","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00262-015-1671-y","article-title":"CEA\/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1","volume":"64","author":"Osada","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.medj.2026.101031_bib154","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fonc.2018.00285","article-title":"Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy","volume":"8","author":"Kobold","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib155","article-title":"Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment","volume":"3","author":"Zhu","year":"2023","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.medj.2026.101031_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.642466","article-title":"PD-1 Inhibition Enhances Blinatumomab Response in a UCB\/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia","volume":"11","author":"Wunderlich","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib157","doi-asserted-by":"crossref","first-page":"575737","DOI":"10.3389\/fonc.2020.575737","article-title":"Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity","volume":"10","author":"Sam","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib158","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.medj.2026.101031_bib159","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","article-title":"Bifunctional PD-1 \u00d7 \u03b1CD3 \u00d7 \u03b1CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia","volume":"132","author":"Herrmann","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib160","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2026.101031_bib161","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1182\/bloodadvances.2021005400","article-title":"An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies","volume":"5","author":"Roider","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.medj.2026.101031_bib162","doi-asserted-by":"crossref","first-page":"76902","DOI":"10.18632\/oncotarget.12357","article-title":"T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2026.101031_bib163","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","article-title":"Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed\/Refractory (R\/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study","volume":"132","author":"Webster","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib164","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2019-131061","article-title":"Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504","volume":"134","author":"Schwartz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib165","first-page":"1495","article-title":"Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies","volume":"130","author":"Topp","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib166","doi-asserted-by":"crossref","first-page":"e19584","DOI":"10.1200\/JCO.2022.40.16_suppl.e19584","article-title":"Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"40","author":"Giri","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib167","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib168","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","article-title":"T Cell Anergy","volume":"21","author":"Schwartz","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib169","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00262-023-03439-x","article-title":"CD33 BiTE\u00ae molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells","volume":"72","author":"Marcinek","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.medj.2026.101031_bib170","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2021-146762","article-title":"Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist","volume":"138","author":"H\u00e4nel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib171","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib172","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2016.01.007","article-title":"Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-\u03baB, NFAT and AP-1","volume":"430","author":"Jutz","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.medj.2026.101031_bib173","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101031_bib174","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/2326-6066.CIR-19-0115","article-title":"Metabolic Consequences of T-cell Costimulation in Anticancer Immunity","volume":"7","author":"Teijeira","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2026.101031_bib175","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib176","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2326-6066.CIR-17-0767","article-title":"Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation","volume":"6","author":"Teijeira","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2026.101031_bib177","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20171068","article-title":"4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses","volume":"215","author":"Menk","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2026.101031_bib178","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101031_bib179","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101031_bib180","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1038\/s41467-021-27613-w","article-title":"CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation","volume":"12","author":"Otano","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101031_bib181","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2024-200096","article-title":"Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r\/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072","volume":"144","author":"Hutchings","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib182","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2026.101031_bib183","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2023-173677","article-title":"Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma (R\/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial","volume":"142","author":"Korfi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib184","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/blood-2024-201466","article-title":"Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients","volume":"144","author":"Jamois","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib185","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/blood-2023-180785","article-title":"Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19\/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific","volume":"142","author":"Rappa","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib186","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2024-201406","article-title":"CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma (R\/R NHL)","volume":"144","author":"Korfi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib187","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1158\/1538-7445.AM2023-5681","article-title":"Abstract 5681: Tetra-specific antibody GNC-038: guidance and navigation gontrol (GNC) molecule development for treatment of CD19+ malignancies","volume":"83","author":"Khalili","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2026.101031_bib188","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib189","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 SYSTEM OF T CELL COSTIMULATION","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib190","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1006\/smim.1998.0157","article-title":"Role of 4-1BB in immune responses","volume":"10","author":"Vinay","year":"1998","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib191","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4049\/jimmunol.150.3.771","article-title":"Inducible T cell antigen 4-1BB. Analysis of expression and function","volume":"150","author":"Pollok","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib192","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.632399","article-title":"Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs","volume":"12","author":"D'Souza","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib193","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood.2019001751","article-title":"Lenalidomide in follicular lymphoma","volume":"135","author":"Flowers","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib194","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.medj.2026.101031_bib195","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14656566.2018.1561865","article-title":"Lenalidomide for the treatment of mantle cell lymphoma","volume":"20","author":"Morabito","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.medj.2026.101031_bib196","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib197","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2026.101031_bib198","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.medj.2026.101031_bib199","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.medj.2026.101031_bib201","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-023-06733-x","article-title":"Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer","volume":"624","author":"Zhou","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib203","article-title":"Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay","volume":"5","author":"Tay","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.medj.2026.101031_bib204","doi-asserted-by":"crossref","first-page":"LT02","DOI":"10.1158\/1538-7445.FCS2023-LT02","article-title":"Abstract LT02: Regulation of Exhausted CD8+ T cell Differentiation by IKZF Transcription Factors","volume":"84","author":"Reading","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2026.101031_bib205","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1538-7445.AM2022-5586","article-title":"Abstract 5586: Demonstrating restoration of T cell function in exhausted T cells with IKZF3 small molecule inhibitor","volume":"82","author":"Hay","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2026.101031_bib206","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed\/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib207","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib208","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.medj.2026.101031_bib209","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1535-7163.MCT-22-0498","article-title":"IMiDs Augment CD3-Bispecific Antibody-Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.medj.2026.101031_bib211","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.medj.2026.101031_bib212","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cpt.651","article-title":"Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment","volume":"101","author":"Yuraszeck","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2026.101031_bib213","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.medj.2026.101031_bib214","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2026.101031_bib215","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/s41467-019-10565-7","article-title":"Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101031_bib216","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08097","article-title":"Enhancing CD8 T-cell memory by modulating fatty acid metabolism","volume":"460","author":"Pearce","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib217","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","article-title":"Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming","volume":"166","author":"Buck","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101031_bib218","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib219","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101031_bib220","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1172\/JCI69589","article-title":"Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101031_bib221","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.immuni.2021.06.007","article-title":"Transforming growth factor-beta-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection","volume":"54","author":"Gabriel","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib222","doi-asserted-by":"crossref","first-page":"909979","DOI":"10.3389\/fimmu.2022.909979","article-title":"CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses","volume":"13","author":"Molony","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib223","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003766","article-title":"JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy","volume":"10","author":"Leclercq","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib224","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.3390\/cancers14215442","article-title":"Role of CAR T Cell Metabolism for Therapeutic Efficacy","volume":"14","author":"Rial Saborido","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2026.101031_bib225","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib226","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.trecan.2024.03.010","article-title":"Immunometabolism of CD8(+) T cell differentiation in cancer","volume":"10","author":"Shi","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib227","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","article-title":"Fueling CARs: metabolic strategies to enhance CAR T-cell therapy","volume":"13","author":"Van der Vreken","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib228","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101031_bib229","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-18-0095","article-title":"PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8(+) T Cells and Facilitates Anti-PD-1 Therapy","volume":"6","author":"Chowdhury","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2026.101031_bib230","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122299","article-title":"Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity","volume":"3","author":"Pilipow","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.medj.2026.101031_bib231","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","article-title":"Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation","volume":"36","author":"Si","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.medj.2026.101031_bib232","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib233","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.medj.2026.101031_bib234","article-title":"Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism","volume":"5","author":"Huang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.medj.2026.101031_bib235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.2834","article-title":"The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells","volume":"15","author":"Kurachi","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib236","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2026.101031_bib237","doi-asserted-by":"crossref","first-page":"1627161","DOI":"10.3389\/fimmu.2025.1627161","article-title":"Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib238","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood-2024-207376","article-title":"CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia","volume":"144","author":"Hoffmann","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib239","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","article-title":"CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","volume":"43","author":"Stahl","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101031_bib240","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression","volume":"27","author":"Xing","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101031_bib241","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib242","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","article-title":"T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies","volume":"40","author":"Blanco","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib243","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.2023023210","article-title":"CD70 CAR T cells secreting an anti-CD33\/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML","volume":"145","author":"Silva","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib244","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1200\/JCO.2024.42.16_suppl.2550","article-title":"Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19\/CD22 CAR-T cells","volume":"42","author":"Arroyo-Rodenas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib245","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2444701","article-title":"Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers","volume":"14","author":"Velasco-Sidro","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2026.101031_bib246","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2570224","article-title":"Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager","volume":"14","author":"G\u00f3mez-Rosel","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2026.101031_bib247","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101031_bib248","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/2326-6066.CIR-22-0565","article-title":"Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function","volume":"11","author":"Renauer","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2026.101031_bib249","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101031_bib250","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.2019004500","article-title":"Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity","volume":"136","author":"Fultang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib251","doi-asserted-by":"crossref","first-page":"1113739","DOI":"10.3389\/fnut.2023.1113739","article-title":"Lactate in the tumor microenvironment: A rising star for targeted tumor therapy","volume":"10","author":"Li","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.medj.2026.101031_bib252","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006287","article-title":"Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies","volume":"11","author":"Lopez","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101031_bib253","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib254","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16152-z","article-title":"B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12","volume":"12","author":"Hunter","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101031_bib255","doi-asserted-by":"crossref","first-page":"169.22","DOI":"10.4049\/jimmunol.204.Supp.169.22","article-title":"Promoting anti-tumor immunity via bispecific T cell engaging cytokine (biteokine) therapy","volume":"204","author":"Do","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib256","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.immuni.2022.01.018","article-title":"Tfh-cell-derived interleukin 21 sustains effector CD8(+) T cell responses during chronic viral infection","volume":"55","author":"Zander","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101031_bib257","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.18632\/oncotarget.24442","article-title":"IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner","volume":"9","author":"Loschinski","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2026.101031_bib258","first-page":"2131","article-title":"Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy","volume":"109","author":"Casey","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.medj.2026.101031_bib259","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.medj.2026.101031_bib260","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101031_bib261","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2024026934","article-title":"STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia","volume":"145","author":"Linder","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101031_bib262","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255536","article-title":"STING agonism turns human T cells into interferon-producing cells but impedes their functionality","volume":"24","author":"Kuhl","year":"2023","journal-title":"EMBO Rep."},{"key":"10.1016\/j.medj.2026.101031_bib263","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101031_bib264","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2026.101031_bib265","article-title":"Guidelines for T cell nomenclature","author":"Masopust","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2026.101031_bib266","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:10:13Z","timestamp":1778253013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":266,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666634026000346"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101031","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: Mechanisms and implications","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101031"}}